ILMN Illumina, Inc. logo

ILMN Illumina, Inc.

Healthcare
$144.41-0.29%ClosedMarket Cap: $21.85B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

21.75

PEG

0.13

P/B

8.26

P/S

4.98

EV/EBITDA

19.15

DCF Value

$-62.74

FCF Yield

4.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

67.7%

Operating Margin

21.5%

Net Margin

19.4%

ROE

34.0%

ROA

13.0%

ROIC

13.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$1.09B$134.0M$
Q4 null$1.16B$334.0M$
FY null$4.34B$850.0M$
Q3 null$1.08B$150.0M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$150.40

Target (Median)

$152.50

Target Range

$122.00 - $170.00

3 Strong Buy8 Buy7 Hold1 Sell2 Strong Sell
CitigroupSell
2026-05-04
Evercore ISI GroupOutperform
2026-05-01
Canaccord GenuityHold
2026-05-01
BarclaysUnderweight
2026-05-01
JP MorganNeutral
2026-05-01

Trading Activity

Insider Trades

View All
Ullem Scott B.director
SellFri May 22
SIEGEL SUSAN Edirector
SellFri May 22
SCHILLER PHILIP Wdirector
SellFri May 22
RICHO ANNAdirector
SellFri May 22
Meister Keith A.director
SellFri May 22

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

1.42

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Peers